Effects of first-trimester fluoxetine exposure on the newborn

Obstetrics and Gynecology

Volumn 89, Issue 5, 1997, Pages 713-718

  Goldstein, David J ^a,b,c   Corbin, Lois A ^a,b,c   Sundell, Karen L ^a,b,c  

^a ELI LILLY AND COMPANY   (United States)

^b Hospital of Indiana   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FETUS; FETUS MALFORMATION; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; FLUOXETINE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031000065     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00070-7     Document Type: Article

References (16)

1. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
2. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
3. McDonald AD. Maternal health and congenital defect: A prospective investigation. N Engl J Med 1958;258:767-74.
4. McIntosh R, Merritt KK, Richards MR, Samuels MH, Bellows MT. The incidence of congenital malformations: A study of 5,964 pregnancies. Pediatrics 1954;14:505-21.
5. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations. J Pediatr 1964;64: 357-61.
6. McBride WZ. Spontaneous abortion. Am Fam Physician 1991;43: 175-82.
7. Keily M. Reproductive and perinatal epidemiology. Boca Raton, Florida: CRC Press, 1991:69.
8. Byrd RA, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994;22:511-8.
9. Pohland RC, Byrd TK, Hamilton M, Koons JR. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989;98:198-205.
10. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23:194-205.
11. Stanford MS, Patton JH. In utero exposure to fluoxetine HC1 increases hematoma frequency at birth. Pharmacol Biochem Behav 1993;45:959-62.
12. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mas-troiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of anti depressants. A collaborative study of the European network of the teratology information services (ENTIS). Reprod Toxicol 1996;10:285-94.
13. Heinonen OP, Slone D, Shapiro S. The teratogenic role of drugs in humans. In: Kaufman DW, ed. Birth defects and drugs in pregnancy. Littleton, Massachusetts: Publishing Sciences Group, Inc., 1977:1-7.
14. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-9.
15. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Epidemiol Rev 1995;17:165-71.
16. Rosa F. Medicaid antidepressant pregnancy exposure outcomes. Reprod Toxicol 1994;8:444-5.